The Fabricated Products (FPR) business segment of H.C. Starck converts technology metal powders: molybdenum (Mo), niobium (Nb), tantalum (Ta) and tungsten (W) into customer-specific semi-finished and...
The very slow progress in the treatment of severe diseases has led to the adoption of a multidisciplinary approach to the targeted delivery and release of drugs, underpinned by nanoscience and...
http://www.azonano.com/article.aspx?ArticleID=1702 | 23 Aug 2006
Oraya® Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a...
http://www.azonano.com/news.aspx?newsID=30804 | 6 Aug 2014
On June 7, multidisciplinary researchers from across UC campuses came together at the Kingsgate Marriott Conference Center to develop new collaborations and research ideas in a unique...
http://www.azonano.com/news.aspx?newsID=30375 | 13 Jun 2014
Lumiphore Inc., a portfolio company of Nanostart
AG, has signed a global cooperation with Algeta ASA (Oslo Stock Exchange,
ticker: ALGETA), a leading company specializing in innovative...
http://www.azonano.com/news.aspx?newsID=20185 | 26 Oct 2010
An international team of physicists at Los Alamos National Laboratory has
succeeded in using intense laser light to accelerate protons to energies never
before achieved. Using this technique,...
http://www.azonano.com/news.aspx?newsID=14447 | 2 Nov 2009
Radioactive elements, or radionuclides, are well-established anticancer agents whose main limitation is that they kill healthy cells almost as easily as they do tumors. But because nanoparticles...
http://www.azonano.com/news.aspx?newsID=4788 | 23 Aug 2007
New piece of medical technology unveiled at the National
Physical Laboratory (NPL) today will help improve the success rates of radiotherapy
cancer treatments. The new clinical electron...
http://www.azonano.com/news.aspx?newsID=8697 | 15 Nov 2008
NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced the successful completion of the first in human study of its lead NanoXray...
http://www.azonano.com/news.aspx?newsID=30265 | 2 Jun 2014
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive...
http://www.azonano.com/news.aspx?newsID=32989 | 10 Jun 2015